
Project details
Israeli medical company seeks market expansion.
Project region | Israel |
---|---|
Industry | Healthcare |
Total value of the target | N/A |
Expected target net rate of return after deducting all taxes and fees | N/A |
Validity period of pending order | 365 |
CONTACT ADVISOR
Project highlights | FDA & CE - 24 patents - initial sales USD 500 million |
---|---|
Project description |
The Israeli company holds 24 patents with new and innovative medical devices. The company has been approved by FDA and CE. The company develops and targets minimally invasive cryoablation therapy for women's health and interventional oncology (kidney cancer, lung cancer, liver cancer, bone cancer, and prostate cancer). The system provides outpatient definitive treatment for breast tumors and ablation of other cancerous tumors in the body. Clinical trials have been completed in Europe, America, and Japan. In Europe, Latin America, Asia, and other markets, initial sales are around USD 500 million. The company also targets breast cancer markets. The goal of the company is to seek investment for market expansion. |

We provide expert advisory and corporate services across Asia, guiding businesses through complex markets and regulations.
Have Any Questions?
Reach out to our local experts, we’ll respond within one business day.
Our Clients
Discover our esteemed global clients across diverse sectors. We believe in providing our clients with exceptional service and a commitment to being their partner for growth in Asia.
See what our clients say about us